[P-32] DIPHOSPHONATE DOSE DETERMINATION IN PATIENTS WITH BONE METASTASES FROM PROSTATIC CARCINOMA

Google Scholar
  • 1 January 1978
    • journal article
    • research article
    • Vol. 19  (1) , 98-104
Abstract
In an initial safety study, 32P (as diphosphonate) was administered i.v. to 5 patients with painful bone metastases from prostatic carcinoma; 2 patients received 9 mCi and 3 were given 3 mCi. Hematological, biochemical, ECG, X-ray, bone-scan data and clinical observation were followed for 2 mo. At both dose levels, bone-marrow depression was noted. One of the patients, who received 9 mCi, had only a slight dip in the levels of circulating white blood cells and platelets. The other 9-mCi patient was the only one with discrete metastases by bone scan; he had bone-marrow depression, from which he recovered, and was the only 1 of the 5 who had relief of bone pain.

This publication has 1 reference indexed in Scilit: